Worth putting on a new thread so maybe more of the HC members...

Worth putting on a new thread so maybe more of the HC members see it.

A 33.5c current valuation for ftt. I guess they are expecting trial success like me. Early snippets of data is very promising.

5x is a big call, but ftt certainly worth more than 6c imho

From Marc Sinatra (lodge partners) on Twitter: "Just released a report on Factor Therapeutics $FTT. Looks highly undervalued. NPV = 33.5 cents/share (fully diluted) prior to phase IIb readout in Q4 CY18. NPV = 52 cents after, if +ve. Multiple catalysts to get it there. It’s a good one! @biotech_daily @asxlongtail @Factor_Tx"